📰 Celularity News
Page 4 - Celularity News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Celularity. Real-time updates on events, politics, business and more.
April 20, 2023
Celularity Inc. (NASDAQ:CELU – Get Rating) was the recipient of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 5,170,000 shares, a growth of 8.8% from the March 15th total of 4,750,000 shares. Approximately 7.4% of the company’s shares are short sold. Based on […]
April 7, 2023
Item 1.01 Entry into a Material Definitive Agreement. Registered Direct Offering On April 4, 2023, Celularity Inc, or Celularity, entered into a securities purchase agreement with an institutional... | April 7, 2023
April 3, 2023
Celularity’s Pre-Request for Designation is based on data demonstrating 100 percent biochemical characterization of the product Celularity intends to submit 510 pre-market notification to the... | April 3, 2023
April 1, 2023
Celularity Inc. (NASDAQ:CELU – Get Rating) was the target of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 4,750,000 shares, a growth of 38.1% from the February 28th total of 3,440,000 shares. Currently, 9.2% of the company’s shares are sold short. Based on […]
April 1, 2023
Celularity Inc. (NASDAQ:CELUW – Get Rating) saw a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 8,700 shares, an increase of 19.2% from the February 28th total of 7,300 shares. Based on an average trading volume of 19,300 shares, the short-interest ratio is currently […]
March 28, 2023
/PRNewswire/ -- Celularity Inc. (Nasdaq: CELU) ("Celularity"), a biotechnology company developing placental-derived allogenic cell therapies and biomaterial...
January 6, 2023
Legacy studies employing a single treatment course of two infusions seven days apart demonstrated greatest benefit in three early studies Data support...
January 4, 2023
Veteran executive brings more than 30 years of biopharmaceutical public relations and public affairs experience...
November 10, 2022
Announced first patient treated in Phase 1/2a clinical trial for CYNK-101 in first-line advanced HER2 positive gastric and gastroesophageal junction...
November 10, 2022
FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing...